Immunosuppression in clinical practice Approaches to individualized therapy

被引：3

作者：

Chan, Andrew ^{[1
]}

Stueve, Olaf ^{[2
]}

von Ahsen, Nicolas ^{[3
]}

机构：

[1] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, D-44791 Bochum, Germany

[2] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dept Neurol, VA N Texas Hlth Care Syst,Neurol Sect,Med Serv, Dallas, TX 75390 USA

[3] Univ Gottingen, Dept Clin Chem, Fac Med, Gottingen, Germany

来源：

JOURNAL OF NEUROLOGY | 2008年 / 255卷 / Suppl 6期

关键词：

mitoxantrone; azathioprine; cyclophosphamide; methotrexate; pharmacogenetics;

D O I：

10.1007/s00415-008-6005-y

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Despite novel immunoactive agents, immunosuppressants still play a considerable role in the treatment of MS, especially in rapidly progressive cases. Given the limited tolerability and potentially severe side effects of most immunosuppressive drugs, identification of patients with a favorable benefit-risk profile is essential. A narrow therapeutic index, with sometimes high interindividual variability in terms of response and side effects may partially be explained by genetic factors affecting different metabolic pathways. Here, we will review practical aspects in the clinical use of immunosuppressants in MS and discuss approaches to individualized treatment schemes, including novel pharmacogenetic strategies.

引用

页码：22 / 27

页数：6

共 46 条

[11] A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine [J].

Dubinsky, MC ;

Reyes, E ;

Ofman, J ;

Chiou, CF ;

Wade, S ;

Sandborn, WJ .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (10) :2239-2247

[12] Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis [J].

Duddy, Martin ;

Niino, Masaaki ;

Adatia, Femina ;

Hebert, Sherry ;

Freedman, Mark ;

Atkins, Harry ;

Kim, Ho Jin ;

Bar-Or, Amit .

JOURNAL OF IMMUNOLOGY, 2007, 178 (10) :6092-6099

[13] Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria [J].

Edan, G ;

Miller, D ;

Clanet, M ;

Confavreux, C ;

LyonCaen, O ;

Lubetzki, C ;

Brochet, B ;

Berry, I ;

Rolland, Y ;

Froment, JC ;

Dousset, V ;

Cabanis, E ;

IbaZizen, MT ;

Gandon, JM ;

Lai, HM ;

Moseley, I ;

Sabouraud, O .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (02) :112-118

[14]

Edon G, 2007, MULT SCLER, V13, pS22

[15] Pharmacogenomics and individualized drug therapy [J].

Eichelbaum, M ;

Ingelman-Sundberg, M ;

Evans, WE .

ANNUAL REVIEW OF MEDICINE, 2006, 57 :119-137

[16] Multiple Sclerosis Registry in Germany Results of the Extension Phase 2005/2006 [J].

Flachenecker, P. ;

Stuke, K. ;

Elias, W. ;

Freidel, M. ;

Haas, J. ;

Pitschnau-Michel, D. ;

Schimrigk, S. ;

Zettl, U. K. ;

Rieckmann, P. .

DEUTSCHES ARZTEBLATT INTERNATIONAL, 2008, 105 (07) :113-119

[17] Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone [J].

Goffette, S ;

van Pesch, V ;

Vanoverschelde, JL ;

Morandini, E ;

Sindic, CJM .

JOURNAL OF NEUROLOGY, 2005, 252 (10) :1217-1222

[18] Combination therapies in multiple sclerosis [J].

Gold, Ralf .

JOURNAL OF NEUROLOGY, 2008, 255 (Suppl 1) :51-60

[19] Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity [J].

Gonsette, RE .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2004, 223 (01) :81-86

[20] LOW-DOSE (7.5-MG) ORAL METHOTREXATE REDUCES THE RATE OF PROGRESSION IN CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS [J].

GOODKIN, DE ;

RUDICK, RA ;

MEDENDORP, SV ;

DAUGHTRY, MM ;

SCHWETZ, KM ;

FISCHER, J ;

VANDYKE, C .

ANNALS OF NEUROLOGY, 1995, 37 (01) :30-40

← 1 2 3 4 5 →